

Paul S Aisen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3782531/publications.pdf>

Version: 2024-02-01

60
papers

21,333
citations

109321

35
h-index

128289

60
g-index

62
all docs

62
docs citations

62
times ranked

19670
citing authors

#	ARTICLE	IF	CITATIONS
1	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.8	17
2	ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trials. <i>JAMIA Open</i> , 2022, 5, oaab119.	2.0	4
3	Early-stage Alzheimer disease: getting trial-ready. <i>Nature Reviews Neurology</i> , 2022, 18, 389-399.	10.1	44
4	Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	7.6	20
5	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. <i>Biological Psychiatry</i> , 2021, 89, 757-765.	1.3	41
6	Detection of β -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fca008.	3.3	51
7	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
8	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. <i>JAMA Network Open</i> , 2021, 4, e2114364.	5.9	68
9	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12135.	3.7	11
10	The search for Alzheimer disease therapeutics "same targets, better trials?". <i>Nature Reviews Neurology</i> , 2020, 16, 597-598.	10.1	11
11	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	9.0	48
12	AHEAD 3-45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). <i>Alzheimer's and Dementia</i> , 2020, 16, e044511.	0.8	14
13	Association Between Common Variants in <i>RBFox1</i> , an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 1288.	9.0	41
14	Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. <i>Brain Communications</i> , 2020, 2, fcaa007.	3.3	69
15	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	9.0	182
16	Predicting the course of Alzheimer's progression. <i>Brain Informatics</i> , 2019, 6, 6.	3.0	40
17	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2019, 82, 110-119.	3.1	11
18	The relative efficiency of time-to-event progression and continuous measures of cognition in presymptomatic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 308-318.	3.7	11

#	ARTICLE	IF	CITATIONS
19	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019, 15, 615-624.	0.8	5
20	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1408-1420.	27.0	397
21	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. <i>CNS Drugs</i> , 2019, 33, 99-106.	5.9	33
22	Unsuccessful trials of therapies for Alzheimer's disease. <i>Lancet</i> , The, 2019, 393, 29.	13.7	31
23	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. <i>NeuroImage: Clinical</i> , 2019, 21, 101574.	2.7	11
24	A simulation study comparing slope model with mixed model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 46-53.	3.7	9
25	Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2018, 90, 145-145.	1.1	1
26	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1691-1703.	27.0	512
27	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 657-668.	2.4	27
28	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , 2018, 14, 1397-1405.	0.8	10
29	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002660.	8.4	131
30	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β . <i>Alzheimer's and Dementia</i> , 2017, 13, 1004-1012.	0.8	139
31	Statistical properties of continuous composite scales and implications for drug development. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 1104-1114.	0.8	23
32	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2305.	7.4	311
33	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.1	136
34	Randomized controlled trials in mild cognitive impairment. <i>Neurology</i> , 2017, 88, 1751-1758.	1.1	35
35	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	3.1	70
36	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	6.2	316

#	ARTICLE	IF	CITATIONS
37	The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 427-437.	2.6	37
38	F5â€04â€03: TRCâ€PAD: Using Runâ€In Data for Screen Failure Reduction. <i>Alzheimer's and Dementia</i> , 2016, 12, P372.	0.8	1
39	Accelerating rates of cognitive decline and imaging markers associated with β^2 -amyloid pathology. <i>Neurology</i> , 2016, 86, 1887-1896.	1.1	42
40	Vitamin E in aging persons with Down syndrome. <i>Neurology</i> , 2016, 86, 2071-2076.	1.1	47
41	Cognitive and functional changes associated with β^2 pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	3.1	28
42	Drug development in Alzheimerâ€™s disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	6.2	323
43	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. <i>BMC Medical Genomics</i> , 2016, 9, 30.	1.5	20
44	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
45	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 205-214.	2.6	57
46	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimerâ€™s disease biomarkers in down syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 239.	2.0	66
47	Brain structure and function as mediators of the effects of amyloid on memory. <i>Neurology</i> , 2015, 84, 1136-1144.	1.1	44
48	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2015, 72, 446.	9.0	142
49	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	12.4	588
50	The Preclinical Alzheimer Cognitive Composite. <i>JAMA Neurology</i> , 2014, 71, 961.	9.0	548
51	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 311-321.	27.0	1,387
52	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	7.1	309
53	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	10.2	3,378
54	Mild cognitive impairment due to Alzheimer disease in the community. <i>Annals of Neurology</i> , 2013, 74, 199-208.	5.3	215

#	ARTICLE	IF	CITATIONS
55	Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984.	0.0	180
56	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	27.0	3,005
57	Testing the Right Target and Right Drug at the Right Stage. <i>Science Translational Medicine</i> , 2011, 3, 111cm33.	12.4	459
58	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 280-292.	0.8	5,550
59	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2010, 133, 3336-3348.	7.6	455
60	ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI). <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S170-S178.	1.3	70